Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 11, 2008, Pages 3033-3042

  Szarewski, Anne ^a   Ambroisine, Laurence ^a   Cadman, Louise ^a   Austin, Janet ^a   Ho, Linda ^a   Terry, George ^a   Liddle, Stuart ^b   Dina, Roberto ^b   McCarthy, Julie ^c   Buckley, Hilary ^c   Bergeron, Christine ^d   Soutter, Pat ^b   Lyons, Deirdre ^c   Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d LABORATOIRE CERBA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HISTOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; VAGINAL SMEARS;

EID: 55849088380     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0508     Document Type: Article

References (21)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
2. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-6.
3. Cuzick J, Clavel C, Petry K-U, et al. Overview of the European and North American studies on HPV testing in primary cervical screening. Int J Cancer 2006;119:1095-101.
4. Almonte M, Ferreccio C, Winkler J, et al. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer 2007;121:796-802.
5. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72.
6. Mayrand MH, Duarte-Franco E, Rodrigues I, et al.; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-88.
7. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97.
8. Kotaniemi-Talonen L, Anttila A, Malila N, et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008;44: 565-71.
9. Ronco G, Giorgi-Rossi P, Carozzi F, et al.; New Technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100: 492-501.
10. Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high risk human papillomavirus testing in population-based cervical screening. Br J Cancer 2005;92: 1800-2.
11. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97:10729.
12. Yoshida T, Fukuda T, Sano T, Kanuma T, Owada N, Nakajima T. Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer 2004;102:100-8.
13. INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer 2005;105:461-7.
14. INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 2007;111:58-66.
15. Stevens MP, Garland SM, Rudland E, Tan J, Quinn MA, Tabrizi SN. Comparison of the Digene Hybrid Capture 2 Assay and Roche Amplicor and Linear Array Human Papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 2007;45: 2130-7.
16. Lillo F. HPV genotyping: are different hybridization methods comparable in detecting high risk infections? Presented at Eurogin 2006, FC4-04.
17. Verdasca N, Pista A, Oliveira A, et al. Comparison of Papillocheck, Clinical Array and Linear Array HPV genotyping assays in a group of Portuguese women. Presented at ISPV Beijing 2007, PS6-20.
18. INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia. Adv Anat Pathol 2006;13:190-4.
19. Carozzi F, Bisanzi S, Sani C, et al. Agreement between the Amplicor Human Papillomavirus Test and the Hybrid Capture II Assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J Clin Microbiol 2007;45:364-9.
20. Halfon P, Trepo E, Antoniotti G, et al. Prospective evaluation of the Hybrid Capture 2 and Amplicor human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance. J Clin Microbiol 2007;45: 313-6.
21. De Francesco MA, Gargiulo F, Schreiber C, Ciravolo G, Salinaro F, Manca N. Comparison of the Amplicor Human Papillomavirus Test and the Hybrid Capture 2 Assay for detection of high-risk human papillomavirus in women with abnormal PAP smear. J Virol Methods 2008;147:10-7.